60 Degrees Pharmaceuticals Identifies Babesia Parasite In 24% Of Participants In Group Of 50 Patients With Chronic Fatigue

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a study conducted by researchers at North Carolina State University, and published in Pathogens.

Results announced today contribute to efforts to confirm a long-held theory within the U.S. vector-borne disease community that Babesia and chronic disease may be linked – specifically, that Babesia infection may prolong recovery times in patients with chronic fatigue.

The results also reinforce the importance of the B-Free Chronic Babesiosis Study (NCT06656351